Ranolazine*: A Metabolic Modulator for the Treatment of Chronic Stable AnginaAnderson, Joe R. PharmD; Nawarskas, James J. PharmDCardiology in Review: July-August 2005 - Volume 13 - Issue 4 - p 202-210 doi: 10.1097/01.crd.0000161979.62749.e7 Drug Highlight Buy Abstract Author InformationAuthors Article MetricsMetrics Ranolazine is a novel new antianginal agent currently under investigation as monotherapy and adjunct therapy for the treatment of chronic stable angina. While the mechanism of action of ranolazine is not completely understood, it is believed to involve a reduction in fatty acid oxidation, ultimately leading to a shift in myocardial energy production from fatty acid oxidation to glucose oxidation. Since the oxidation of glucose requires less oxygen than the oxidation of fatty acids, ranolazine can help maintain myocardial function in times of ischemia. In addition, ranolazine has minimal effect on blood pressure and heart rate. Ranolazine, by inhibiting cellular ionic channels, prolongs the corrected QT interval. However, ranolazine has not yet been associated with any incidences of ventricular arrhythmia. The clinical data with ranolazine focuses on its use in chronic stable angina, where it has been shown to increase exercise tolerance and decrease angina compared with placebo, as well as in combination with beta-blockers and calcium channel blockers. The use of ranolazine for other cardiac conditions and the effect of ranolazine on morbidity and mortality remains to be determined. Ongoing clinical trials will help further establish the role of ranolazine in the treatment of cardiovascular disorders. From the University of New Mexico College of Pharmacy, Albuquerque, NM. *Updated from Anderson JR, Khou S, Nawarskas JJ. Ranolazine. A potential new treatment for chronic stable angina. Heart Dis. 2001;3:263–269. Reprints: Joe R. Anderson, PharmD, College of Pharmacy, MSC09 5360, 1 University of New Mexico, Albuquerque, NM 87131-0001. E-mail: firstname.lastname@example.org. © 2005 Lippincott Williams & Wilkins, Inc.